Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00351715
(Study stopped due to low accrual)
The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the outpatient population before conducting an appropriately powered phase III study. Thus the primary purpose of this study is to determine the proportion of patients who are successfully titrated to an optimal dose of sublingual (Under the tongue) methadone and then studied at that optimal dose with successive episodes of breakthrough pain.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Pain due to cancer or its treatment; controlled baseline pain;
episodes of breakthrough pain every day that are "4/10" in severity or greater, ;
ast 10 minutes or longer, and
are responsive to short acting oral opioids such as morphine or hydromorphone;
are able to hole a volume of 1.0cc of water under the tongue for a 5-minute period; are able to provide written informed consent;
are able to fill out the study forms
Severe underlying respiratory disease such that an investigator is wary about the risk of respiratory failure from modest doses of opioid;
prior sensitivity to methadone;
currently are being administered methadone;
have breakthrough pain that in the opinion of the investigator is likely to change within the next seven days (recent or imminent radiation therapy to the main site of pain,
new chemotherapy or use of an injectable bisphosphonate likely to alter the pain, new use corticosteroids within the past week with a corresponding change in pain, or other interventions judged likely to alter pain);
are clinically unstable or have a life expectancy of less than one month making completion of the trial unlikely